CliffBio
small molecule

GVOKE PFS

GLUCAGON

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyXeris Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameGVOKE PFS
Active ingredientGLUCAGON
Strength0.5MG/0.1ML (0.5MG/0.1ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
9649364April 2036product
11590205April 2036product

More from Xeris Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GVOKE PFS patent cliff — loss of exclusivity April 2036 | CliffBio